Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes

NCT00020969 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00020969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00020969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes
Lead sponsor
CTI BioPharma
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2001
Completion date
January 31, 2005
Enrollment
Not reported
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms